NI200700191A - Construcciones de ácido nucleico - Google Patents

Construcciones de ácido nucleico

Info

Publication number
NI200700191A
NI200700191A NI200700191A NI200700191A NI200700191A NI 200700191 A NI200700191 A NI 200700191A NI 200700191 A NI200700191 A NI 200700191A NI 200700191 A NI200700191 A NI 200700191A NI 200700191 A NI200700191 A NI 200700191A
Authority
NI
Nicaragua
Prior art keywords
nucleic acid
hcmv
promoter sequence
chimeric promoter
exon
Prior art date
Application number
NI200700191A
Other languages
English (en)
Inventor
James Fuller
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of NI200700191A publication Critical patent/NI200700191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Una construcción de ácido nucleico que comprende una secuencia promotora quimérica y un sitio de clonación para la inserción de una secuencia de codificación en enlace operable con un promotor quimérico, en donde la secuencia promotora quimérica comprende: (a) una secuencia promotora temprana inmediata Hcmv; (b) el exón 1 y al menos parte del exón 2 del gen temprano inmediatamente principal hCMV; y (c) un intrón heterólogo provisto en el lugar de la región del intrón A del gen temprano inmediato principal hCMV.
NI200700191A 2005-02-01 2007-07-30 Construcciones de ácido nucleico NI200700191A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64838205P 2005-02-01 2005-02-01
US67249705P 2005-04-19 2005-04-19
GBGB0507997.5A GB0507997D0 (en) 2005-02-01 2005-04-20 Nucleic acid constructs

Publications (1)

Publication Number Publication Date
NI200700191A true NI200700191A (es) 2008-02-05

Family

ID=36178086

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700191A NI200700191A (es) 2005-02-01 2007-07-30 Construcciones de ácido nucleico

Country Status (20)

Country Link
US (1) US20100221349A1 (es)
EP (1) EP1850869A2 (es)
JP (1) JP2008528020A (es)
KR (1) KR20070100403A (es)
CN (1) CN101155597A (es)
AP (1) AP2007004137A0 (es)
AU (1) AU2006210716A1 (es)
BR (1) BRPI0607119A2 (es)
CA (1) CA2596731A1 (es)
EA (1) EA011557B1 (es)
GB (1) GB0507997D0 (es)
IL (1) IL184653A0 (es)
MA (1) MA29274B1 (es)
MX (1) MX2007009164A (es)
NI (1) NI200700191A (es)
NO (1) NO20074421L (es)
SG (1) SG158902A1 (es)
TN (1) TNSN07295A1 (es)
WO (1) WO2006082398A2 (es)
ZA (1) ZA200707522B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG147430A1 (en) * 2003-10-10 2008-11-28 Powderject Vaccines Inc Nucleic acid constructs
CA2632261A1 (en) * 2005-12-05 2007-06-14 Guava Technologies Particle-based analyte characterization
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2715078C (en) * 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
AU2008331673B2 (en) 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
WO2009092038A1 (en) * 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
DK2358386T3 (en) 2008-11-28 2017-02-13 Statens Seruminstitut Optimized flu vaccine
ES2759015T3 (es) 2010-02-10 2020-05-07 Mayo Found Medical Education & Res Métodos y materiales para tratar el cáncer
WO2013138697A1 (en) * 2012-03-15 2013-09-19 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN103740715B (zh) * 2013-12-25 2016-03-23 北京大北农科技集团股份有限公司 嵌合启动子及其用途
CN103901209B (zh) * 2014-02-18 2016-05-25 王明丽 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒
WO2015143221A1 (en) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10188713B2 (en) 2014-03-19 2019-01-29 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN105120042B (zh) * 2015-09-09 2019-02-12 小米科技有限责任公司 移动终端
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US20210187064A1 (en) * 2018-05-07 2021-06-24 Administrators Of The Tulane Educational Fund Mutated e. coli enterotoxins as anti-inflammatory agents
WO2022155226A1 (en) * 2021-01-12 2022-07-21 Duke University Compositions and methods for the genetic manipulation of the influenza virus
WO2024097894A1 (en) * 2022-11-04 2024-05-10 RNAimmune, Inc. Compositions and methods of ribonucleic acid vaccines encoding nye-so-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) * 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
NZ279995A (en) * 1994-01-21 1998-04-27 Powderject Vaccines Inc Gas driven gene delivery instrument with a conical exit nozzle and a cartridge with an arcuate, linear passage
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
EP1373524B1 (en) * 2000-10-13 2006-04-12 Chiron Corporation Cytomegalovirus intron a fragments
WO2003004055A2 (en) * 2000-11-27 2003-01-16 Powderject Vaccines, Inc. Nucleic acid adjuvants
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
SG147430A1 (en) * 2003-10-10 2008-11-28 Powderject Vaccines Inc Nucleic acid constructs
AU2004280630A1 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Method

Also Published As

Publication number Publication date
US20100221349A1 (en) 2010-09-02
ZA200707522B (en) 2008-08-27
EA011557B1 (ru) 2009-04-28
EA200701643A1 (ru) 2008-02-28
NO20074421L (no) 2007-10-31
CA2596731A1 (en) 2006-08-10
BRPI0607119A2 (pt) 2009-08-11
MX2007009164A (es) 2008-03-13
WO2006082398A2 (en) 2006-08-10
AP2007004137A0 (en) 2007-08-31
EP1850869A2 (en) 2007-11-07
JP2008528020A (ja) 2008-07-31
CN101155597A (zh) 2008-04-02
GB0507997D0 (en) 2005-05-25
IL184653A0 (en) 2007-12-03
SG158902A1 (en) 2010-02-26
AU2006210716A1 (en) 2006-08-10
WO2006082398A3 (en) 2006-10-19
TNSN07295A1 (en) 2008-12-31
KR20070100403A (ko) 2007-10-10
MA29274B1 (fr) 2008-02-01

Similar Documents

Publication Publication Date Title
NI200700191A (es) Construcciones de ácido nucleico
NO20062080L (no) Nukleinsyrekonstrukter
BRPI0813003A2 (pt) Promotor
GB0317466D0 (en) Use
MX2009007001A (es) Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.
DK2199389T3 (da) Mutant AOX1 promotere
WO2005102034A3 (en) Regulatory sequences for expressing gene products in plant reproductive tissue
ES2531135T3 (es) Fitasas, ácidos nucleicos que las codifican y métodos para su producción y uso
AR029731A1 (es) Aislamiento y caracterizacion de un promotor de actina especifico de fibra de algodon
NZ600690A (en) Fkbp-l and uses thereof
AR054597A1 (es) Desarrollo de nuevo germoplasma empleando segregados de cruces transgenicos
PE20131401A1 (es) Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo
NZ601101A (en) Use of cry1da in combination with cry1ca for management of resistant insects
MX2011000281A (es) Fibrinogeno recombinante.
EP4065701A4 (en) CONSTRUCTS, COMPOSITIONS AND METHODS THEREOF WITH IMPROVED GENOMEDITING EFFICIENCY AND SPECIFICITY
CO5590933A2 (es) Composicion y metodo para el tratamiento de la diabetes
TW200625342A (en) Fuel-element for a boiling-water reactor
AR021056A1 (es) Adn que comprende un gen especifico de antera de arroz y planta transgenica transformada con el mismo
DE60335497D1 (de) Ergillus-phytasen
WO2010026219A3 (en) New tomato ethylene response factors and uses thereof
CR9358A (es) Construcciones de acido nucleico
MX2007004271A (es) Enzimas involucradas en la sintesis de triterpenos.
WO2003101497A8 (en) Knockout mice and their use
MX2023004052A (es) Constructos de acido nucleico para transcripcion de arn asociado a un virus (arn va).
WO2018115473A3 (en) VARIANTS OF STABLE PROTEASE